B+
Bull case
25%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
MGNX
MacroGenicsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
MGC026's interim activity and the company's stated $327 million pro forma cash and securities position with runway guidance through 2028 support continued development without an obvious immediate financing deadline. Both figures are company-reported, and the clinical data remain early.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -6.0.
What can break
Grade 3 or higher treatment-related adverse events occurred in 51% of the overall MGC026 safety population, notably neutropenia and anemia. Company release [#IR-2026-10-23]
Momentum
37
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.35 · Bull $4.00 · Bear $1.20Analysis 2026-10-24; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-24 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $8.00
Why
Momentum37 · Δ7d +3.2
Value41 · Δ7d -0.1
Sentiment100 · Δ7d -6.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -6.0.
Contradictions & invalidation
- • Grade 3 or higher treatment-related adverse events occurred in 51% of the overall MGC026 safety population, notably neutropenia and anemia. Company release [#IR-2026-10-23]
- • MGC028 readout timing, MGC026 enrollment and the planned combination study remain execution-dependent. [#SEC-8K-2026-08-13] [#IR-2026-10-23]
- • The MGC026 head-and-neck response set contains only 22 evaluable patients and includes two unconfirmed responses.
Catalyst clock
2026-10-27
Market digestion of MGC026 interim data
Lead driver: Sentiment · See AI snapshot
Momentum
37
8% active weight
Current posture
7d trendSoftening
Δ7d
+3.2
Δ21d
-34.3
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
100
45% active weight
Current posture
7d trendSoftening
Δ7d
-6.0
Δ21d
+6.3
Why this grade
Composite grade A. Momentum 37.3 / Value 40.6 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-24. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$2.35
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.20
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$143.33M
Beta
1.50
Shares Out
63.7M
P/E (TTM) · Derived
-1.9
P/S (TTM)
0.85
P/FCF (TTM) · Derived
-2.18
Rev YoY
+378.0%
EPS YoY
-153.4%
Gross Margin
+77.9%
Op Margin
-24.3%
Net Debt
-$83.15M
Current Ratio
2.96
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data